Cargando…

Treatment of mouse liver slices with cholestatic hepatotoxicants results in down-regulation of Fxr and its target genes

BACKGROUND: Unexpected cholestasis substantially contributes to drug failure in clinical trials. Current models used for safety assessment in drug development do not accurately predict cholestasis in humans. Therefore, it is of relevance to develop new screening models that allow identifying drugs w...

Descripción completa

Detalles Bibliográficos
Autores principales: Szalowska, Ewa, Stoopen, Geert, Groot, Maria J, Hendriksen, Peter JM, Peijnenburg, Ad ACM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852711/
https://www.ncbi.nlm.nih.gov/pubmed/24112857
http://dx.doi.org/10.1186/1755-8794-6-39
_version_ 1782478708149321728
author Szalowska, Ewa
Stoopen, Geert
Groot, Maria J
Hendriksen, Peter JM
Peijnenburg, Ad ACM
author_facet Szalowska, Ewa
Stoopen, Geert
Groot, Maria J
Hendriksen, Peter JM
Peijnenburg, Ad ACM
author_sort Szalowska, Ewa
collection PubMed
description BACKGROUND: Unexpected cholestasis substantially contributes to drug failure in clinical trials. Current models used for safety assessment in drug development do not accurately predict cholestasis in humans. Therefore, it is of relevance to develop new screening models that allow identifying drugs with cholestatic properties. METHODS: We employed mouse precision cut liver slices (PCLS), which were incubated 24 h with two model cholestatic compounds: cyclosporin A (CsA) and chlorpromazine (CPZ). Subsequently, transcriptome analysis using DNA microarrays and q-PCR were performed to identify relevant biological processes and biomarkers. Additionally, histology was carried out and levels of triglycerides (TG) and bile acids (BA) were measured. To verify the ex vivo mouse data, these were compared with publically available human data relevant for cholestasis. RESULTS: Whole genome gene expression analysis showed that CsA up-regulated pathways related to NF-κB, ER stress and inflammation. Both CsA and CPZ down-regulated processes related to extracellular matrix (ECM) remodelling, BA homeostasis, Fxr signalling, and energy metabolism. The differential expression of a number of characteristic genes (e.g. Abcg5, Abcg8, Klf15, and Baat) could be confirmed by q-PCR. Histology revealed that CsA but not CPZ induced “ballooning” of hepatocytes. No effects on TG and BA levels were observed after incubation of PCLS with CsA and CPZ. A substantial number of processes altered in CsA- and CPZ-treated mouse PCLS ex vivo was also found to be affected in liver biopsies of cholestatic patients. CONCLUSION: The present study demonstrated that mouse PCLS can be used as a tool to identify mechanisms of action of cholestatic model compounds. The induction of general stress responses and down-regulated Fxr signalling could play a role in the development of drug induced cholestasis. Importantly, comparative data analysis showed that the ex vivo mouse findings are also relevant for human pathology. Moreover, this work provides a set of genes that are potentially useful to assess drugs for cholestatic properties.
format Online
Article
Text
id pubmed-3852711
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38527112013-12-06 Treatment of mouse liver slices with cholestatic hepatotoxicants results in down-regulation of Fxr and its target genes Szalowska, Ewa Stoopen, Geert Groot, Maria J Hendriksen, Peter JM Peijnenburg, Ad ACM BMC Med Genomics Research Article BACKGROUND: Unexpected cholestasis substantially contributes to drug failure in clinical trials. Current models used for safety assessment in drug development do not accurately predict cholestasis in humans. Therefore, it is of relevance to develop new screening models that allow identifying drugs with cholestatic properties. METHODS: We employed mouse precision cut liver slices (PCLS), which were incubated 24 h with two model cholestatic compounds: cyclosporin A (CsA) and chlorpromazine (CPZ). Subsequently, transcriptome analysis using DNA microarrays and q-PCR were performed to identify relevant biological processes and biomarkers. Additionally, histology was carried out and levels of triglycerides (TG) and bile acids (BA) were measured. To verify the ex vivo mouse data, these were compared with publically available human data relevant for cholestasis. RESULTS: Whole genome gene expression analysis showed that CsA up-regulated pathways related to NF-κB, ER stress and inflammation. Both CsA and CPZ down-regulated processes related to extracellular matrix (ECM) remodelling, BA homeostasis, Fxr signalling, and energy metabolism. The differential expression of a number of characteristic genes (e.g. Abcg5, Abcg8, Klf15, and Baat) could be confirmed by q-PCR. Histology revealed that CsA but not CPZ induced “ballooning” of hepatocytes. No effects on TG and BA levels were observed after incubation of PCLS with CsA and CPZ. A substantial number of processes altered in CsA- and CPZ-treated mouse PCLS ex vivo was also found to be affected in liver biopsies of cholestatic patients. CONCLUSION: The present study demonstrated that mouse PCLS can be used as a tool to identify mechanisms of action of cholestatic model compounds. The induction of general stress responses and down-regulated Fxr signalling could play a role in the development of drug induced cholestasis. Importantly, comparative data analysis showed that the ex vivo mouse findings are also relevant for human pathology. Moreover, this work provides a set of genes that are potentially useful to assess drugs for cholestatic properties. BioMed Central 2013-10-10 /pmc/articles/PMC3852711/ /pubmed/24112857 http://dx.doi.org/10.1186/1755-8794-6-39 Text en Copyright © 2013 Szalowska et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Szalowska, Ewa
Stoopen, Geert
Groot, Maria J
Hendriksen, Peter JM
Peijnenburg, Ad ACM
Treatment of mouse liver slices with cholestatic hepatotoxicants results in down-regulation of Fxr and its target genes
title Treatment of mouse liver slices with cholestatic hepatotoxicants results in down-regulation of Fxr and its target genes
title_full Treatment of mouse liver slices with cholestatic hepatotoxicants results in down-regulation of Fxr and its target genes
title_fullStr Treatment of mouse liver slices with cholestatic hepatotoxicants results in down-regulation of Fxr and its target genes
title_full_unstemmed Treatment of mouse liver slices with cholestatic hepatotoxicants results in down-regulation of Fxr and its target genes
title_short Treatment of mouse liver slices with cholestatic hepatotoxicants results in down-regulation of Fxr and its target genes
title_sort treatment of mouse liver slices with cholestatic hepatotoxicants results in down-regulation of fxr and its target genes
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852711/
https://www.ncbi.nlm.nih.gov/pubmed/24112857
http://dx.doi.org/10.1186/1755-8794-6-39
work_keys_str_mv AT szalowskaewa treatmentofmouseliversliceswithcholestatichepatotoxicantsresultsindownregulationoffxranditstargetgenes
AT stoopengeert treatmentofmouseliversliceswithcholestatichepatotoxicantsresultsindownregulationoffxranditstargetgenes
AT grootmariaj treatmentofmouseliversliceswithcholestatichepatotoxicantsresultsindownregulationoffxranditstargetgenes
AT hendriksenpeterjm treatmentofmouseliversliceswithcholestatichepatotoxicantsresultsindownregulationoffxranditstargetgenes
AT peijnenburgadacm treatmentofmouseliversliceswithcholestatichepatotoxicantsresultsindownregulationoffxranditstargetgenes